New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in ...

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient populationEncouraging safety and ...
TCTMD

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Skye also reported changes in waist circumference, a key secondary endpoint. Nimacimab plus semaglutide showed a least-means squared (SE) change of -11.26cm (1.16cm) in waist circumference versus ...
Healio

Oral semaglutide reduces body weight, improves glycemic parameters, CV risk factors

Oral semaglutide improved glycemic parameters and cardiovascular risk factors for adults with overweight or obesity, with ...
Healio

Oral anticoagulation alone preferable in stable patients with atrial fibrillation, stent

In patients with atrial fibrillation who had a drug-eluting stent implanted at least 1 year prior, oral anticoagulation alone was noninferior to oral anticoagulation plus clopidogrel, researchers ...
Morningstar

SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late ...

- Results from the BL-B01D1-303 (NCT06118333) phase III trial presented in a late-breaking oral presentation at ESMO represents the first data readout for iza-bren from a registration enabling study ...
TipRanks on MSN

Rhythm announces presentation of four datasets at ObesityWeek

Rhythm Pharmaceuticals (RYTM) announced that Rhythm and its partners delivered four Rhythm data presentations at ObesityWeek 2025, held last week ...
PharmiWeb

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy(R) in a pill*) at ObesityWeek(R) 2025, including demonstrated reductions in cardiovascular risk factors

The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...